Order Article Reprints

Fan L, Zhang Y, Maguire P, Muston D, Monberg M, Earla JR, Mihai A, Gulati P. Cost Comparison of Adverse Event Management among Breast and Ovarian Cancer Patients Treated with Poly (ADP-ribose) Polymerase Inhibitors: Analysis Based on Phase 3 Clinical Trials. Journal of Market Access & Health Policy. 2022; 10(1):2078474. https://doi.org/10.1080/20016689.2022.2078474

Fan, Lin, Yuanyuan Zhang, Peter Maguire, Dominic Muston, Matthew Monberg, Jagadeswara Rao Earla, Adela Mihai, and Poonam Gulati. 2022. "Cost Comparison of Adverse Event Management among Breast and Ovarian Cancer Patients Treated with Poly (ADP-ribose) Polymerase Inhibitors: Analysis Based on Phase 3 Clinical Trials" Journal of Market Access & Health Policy 10, no. 1: 2078474. https://doi.org/10.1080/20016689.2022.2078474

Fan, L., Zhang, Y., Maguire, P., Muston, D., Monberg, M., Earla, J. R., Mihai, A., & Gulati, P. (2022). Cost Comparison of Adverse Event Management among Breast and Ovarian Cancer Patients Treated with Poly (ADP-ribose) Polymerase Inhibitors: Analysis Based on Phase 3 Clinical Trials. Journal of Market Access & Health Policy, 10(1), 2078474. https://doi.org/10.1080/20016689.2022.2078474